French Healthcare

🇫🇷 **MEDICA 2024: Showcasing French Excellence in Healthcare** 🇫🇷 From November 11th to 14th, Düsseldorf will host the largest international trade fair for medical technologies, serving as a key meeting point for healthcare professionals. **This year, the French Pavilion will be a hub of innovation:** ✨ **133 French companies** will present their expertise on the international stage, ready to establish strategic partnerships. ✨ Join us to explore innovative solutions that are shaping the future of healthcare. **Seize this unique opportunity:** 👉 **Review the profiles of the exhibiting companies and plan your visits here:** [Discover the French Pavilion here] https://lnkd.in/eQ2P5Dqg **Join us in celebrating French excellence and innovation at #MEDICA2024.** Prepare to be informed about the talents and technologies that contribute to France's reputation in the healthcare sector. 🔔 **Initiate new collaborations and join us in Düsseldorf!** #FrenchHealthcare #ChooseFrance #Medica2024

Tic Tac, #PrixGalienUSA is in a few days away. Will you be there on November 7?

Stay Tuned with Business France and French Healthcare 🗓️

Exciting News in Rare Disease Care in France! 🇫🇷 France is making significant strides in rare disease treatment with the accreditation of 132 new reference centers, bringing the total to 603 centers. This initiative, backed by a €36 million investment, aims to improve care, accelerate diagnosis, and foster innovative therapies. The comprehensive plan, PNMR4, will be unveiled in September 2024, promising a brighter future for the 3.5 million people affected by rare diseases in France. 🌟 Discover more about this groundbreaking initiative! #FrenchHealthcare #ChooseFrance #Research

Verdot strengthens its presence in France with a new investment under the France 2030 plan. Verdot, a key player in biopharmaceutical equipment, announces a significant expansion project in Riom, France. This initiative aims to boost French industrial innovation and competitiveness. Key points of the project: Construction of a new headquarters Establishment of a modern production facility Goal: double the current production capacity This strategic development aims to: Enhance Verdot’s innovation capabilities Meet growing biopharma market demand Support the rise of bioproduction in France Charles Ruban, CEO of VERDOT comments: "This investment strengthens our ability to innovate and meet the evolving needs of the biopharmaceutical sector." #FrenchHealthcare #ChooseFrance #France2030 #Bioproduction

🔎 Innovation serving everyone! 💡 The Paralympic Games of #Paris2024 have become a hub of technological advancement, where the development of cutting-edge equipment not only boosts athletes' performances but also has far-reaching benefits for society. Experts like Elodie-Doyen, a rehabilitation engineer, are at the forefront of this innovation. Her work, alongside researchers and engineers from top institutions like Institut Polytechnique de Paris, focuses on optimising prostheses for disabled athletes, particularly long jumpers. These advancements help refine not only the performance of elite athletes but also contribute to the development of everyday prosthetics, enhancing mobility and accessibility for thousands worldwide. From ultralightweight wheelchairs to prosthetic limbs that mimic natural movement, these innovations are pushing the boundaries of what’s possible in sport and beyond. 🌍 The promise for the future? By constantly improving these technologies, we’re not just transforming the lives of athletes. We’re also paving the way for a more inclusive society, where everyone benefits from enhanced mobility solutions and greater accessibility. 👉 Get inspired by how these French innovations are shaping a more inclusive and accessible world! #Innovation #ParalympicGames #ChooseFrance #FrenchHealthcare #Accessibility #Inclusion

A multidisciplinary French team, led by Professor Damien Léger (Université Paris Cité-VIFASOM), has developed a method and trained AI to detect sleep deprivation. Their work is published in PLoS Computational Biology. #FrenchHealthcare #ChooseFrance #MentalHealth

🌟 Genomic Medicine Breakthrough: AI Revolutionising Ophthalmology Treatments 🌟 We are excited to announce a groundbreaking partnership between genomic medicine and artificial intelligence that promises to revolutionise treatments for retinal diseases. Two innovative start-ups from the Genopole in Evry—WhiteLab Genomics and ADLIN Science—are collaborating with the renowned Institut de la Vision to develop targeted gene therapies, drastically reducing development times. 🔬 About the Partnership: The Institut de la Vision, a leading research centre for vision-related diseases, has joined forces with WhiteLab Genomics, an AI specialist in genomic medicine, and ADLIN Science, a digital platform that supports researchers in data management. Together, they are pioneering new gene therapies in ophthalmology with the support of a €4 million budget from the "France 2030" investment plan, backed equally by the State and the Ile-de-France region. 🚀 Our Ambitious Project: Over the next three years, our collaborative effort, named GEAR, aims to overcome a significant challenge in gene therapy: delivering therapeutic genes into diseased cells. Unlike conventional treatments requiring daily pills, gene therapies—administered just once—promise a lifetime cure. 🔑 Our Innovative Approach: Using AI, we will identify the optimal transport system for delivering the therapeutic gene to target cells using a harmless virus (AAV). "We will identify the locks, design the keys, and modify this transport system to specifically reach these difficult-to-target cells," explains Timothé Cynober, director of business development at WhiteLab Genomics. 📈 Broad Impact and Future Potential: Deniz Dalkara, research director at the Institut de la Vision, highlights that the tool being developed will be applicable to all diseases by simply changing the gene. This holds significant potential for conditions like age-related macular degeneration (AMD), which affects one in three people over 90. 💡 Efficiency and Cost Savings: AI will play a crucial role in achieving the best transport system efficiently, reducing R&D timelines by 40% and experiment-related costs by 30%, according to BCG. ADLIN Science is working on structuring vast amounts of data to facilitate seamless communication between IT and scientific teams, ensuring good traceability. 🗣 Collaborating to improve healthcare: "Together, we aim to harness the power of artificial intelligence to revolutionize treatments and improve outcomes for patients in need," says David Del Bourgo, CEO of WhiteLab Genomics. Paul Rinaudo, CEO of ADLIN Science, adds: "We are a facilitator enabling this revolutionary collaboration." This journey into genomic medicine and AI could pave the way for new treatments and better patient outcomes. #Innovation #FrenchHealthcare #Attractiveness #ChooseFrance 🔗 Read More about these French Healthcare news : https://ow.ly/ugya50Sn8af

The French Pavilion at ReBuild Ukraine: Health & Rehabilitation 2024 in Poland is now open! The 3rd edition of ReBuild Ukraine in Poland will be entirely dedicated to the reconstruction and modernization of the Ukrainian healthcare system. Join us at REBUILD UKRAINE HEALTH AND REHABILITATION and meet the 12 French companies taking part in this new edition from June 24 to 25 in Warsaw. Discover the companies that contribute to France's influence on the international stage and spot their latest cutting-edge innovations. Go here 👉 https://bit.ly/45Dy4IB to discover the exhibitors of the French pavilion. 👏 We would like to thank ✅ the 12 companies 🔵 ⚪️ 🔴 of the French Pavilion who represent the excellence of French innovation. #FrenchHealthcare #ChooseFrance

🌟 Breaking News in Cancer Treatment: Adcytherix Obtains a Record €30M in Seed Funding! 🌟 We're thrilled to announce that Adcytherix a pioneering biotech company based in Marseille, has secured a record-breaking €30 million in seed funding. This monumental achievement sets the stage for Adcytherix to become a leader in next-generation immuno-oncology treatments. 🔬 About Adcytherix: Founded by the visionary team behind Emergence Therapeutics—recently acquired by Eli Lilly for €435 million—Adcytherix is on a mission to revolutionise cancer treatment with Antibody Drug Conjugates (ADCs). Unlike traditional chemotherapy, ADCs specifically target tumour cells, sparing healthy cells and minimising side effects. 🚀 Our Ambitious Journey: With strategic investments led by Pontifax Venture Capital and contributions from industry giants like Pureos Bioventures, KKR, and RA Capital Management, we’re well-positioned to lead the ADC market. Our goal is to enter clinical trials by 2026 with at least three groundbreaking therapies targeting cancers with unmet needs, such as colon, stomach, oesophagus, and lung cancers. 💡 Our Innovative Model: Under the leadership of Jack Elands, Adcytherix is leveraging a unique, agile organisational structure. This approach, previously validated by EmergenceTherapeutics, allows us to rapidly advance our drug candidates. Partnering with MimAbs, a specialist in antibody-based immunotherapy, we’re poised to make significant strides in the fight against cancer. 📈 Looking Ahead: As we assemble a dedicated team of top-tier experts, we anticipate a Series A funding round exceeding €100 million by 2025. According to GlobalData, the ADC market is projected to reach $15 billion by then, doubling its size from 2022. Join us on this exciting journey as we work to bring innovative cancer treatments to patients worldwide. Together, we can make a lasting impact in the fight against cancer. 🔗 Read More about this French Healthcare company : https://ow.ly/fC5650Sn2Ec #FrenchHealthcare #Pharma #Oncology #ChooseFrance